Immune thrombocytopenia in chronic myelomonocytic leukemia

European Journal of Haematology

Volumn 93, Issue 6, 2014, Pages 521-526

  Hadjadj, Jérôme ^a,b,c   Michel, Marc ^b,d,e   Chauveheid, Marie Paule ^a,b,c   Godeau, Bertrand ^b,d,e   Papo, Thomas ^a,b,c,f   Sacre, Karim ^a,b,c,f  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

Author keywords

Chronic myelomonocytic leukemia; Immune thrombocytopenia; Review

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; DANAZOL; DAPSONE; HYDROXYUREA; IMMUNOGLOBULIN; RITUXIMAB; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR; VINCA ALKALOID;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CHRONIC KIDNEY FAILURE; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; CYTOGENETICS; DIABETES MELLITUS; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNE THROMBOCYTOPENIA; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MIDDLE AGED; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PROSTATE CANCER; RETROSPECTIVE STUDY; SEX DIFFERENCE; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTE LIFESPAN; THROMBOCYTOPENIA; TUBERCULOSIS; VERY ELDERLY; BONE MARROW; CASE REPORT; COMPLICATION; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; PATHOLOGY; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RISK FACTOR; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84911375681     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12393     Document Type: Article

References (21)

1. Steensma DP, Tefferi A, Li CY. Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. Leuk Res 2003;27:775-82.
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
3. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011;117:4190-207.
4. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005;90:829-32.
5. Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:610-9.
6. Bourgeois E, Caulier MT, Rose C, Dupriez B, Bauters F, Fenaux P. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. Leukemia 2001;15:950-3.
7. Fukuda M, Horibe K, Miyajima Y, Matsumoto K, Kozaki T, Komiyama A. Chronic myelomonocytic leukemia developed 9 years after the diagnosis of idiopathic thrombocytopenic purpura in a child. Rinsho Ketsueki 1994;35:609-15.
8. Mainwaring CJ, Shutt J, James CM. Not all cases of idiopathic thrombocytopenic purpura [correction of purpura] are what they might first seem. Clin Lab Haematol 2002;24:261-2.
9. Saif MW, Hopkins JL, Gore SD. Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 2002;43:2083-92.
10. Sawanobori M, Nakagawa Y, Inoue Y, Suzuki K, Shinohara T, Takemura T. Chronic myelomonocytic leukemia developed 7 years after the onset of idiopathic thrombocytopenic purpura like syndrome. Rinsho Ketsueki 1997;38:222-7.
11. Ural AU, Kaptan K, Avcu F, Guran S, Beyan C, Durmus O, Yalcin A. Chronic myelomonocytic leukemia developed 2 years after the onset of immune thrombocytopenic purpura like syndrome. Haematologia (Budap) 2000;30:221-4.
12. Bowen DT. Chronic myelomonocytic leukemia: lost in classification? Hematol Oncol 2005;23:26-33.
13. Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004;45:1311-8.
14. Patnaik MM, Padron E, LaBorde RR, et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 2013;27:1504-10.
15. Castro M, Conn DL, Su WP, Garton JP. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1991;18:721-7.
16. Enright H, Jacob HS, Vercellotti G, Howe R, Belzer M, Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995;91:403-8.
17. Al Ustwani O, Ford LA, Sait SJ, et al. Myelodysplastic syndromes and autoimmune diseases-case series and review of literature. Leuk Res 2013;37:894-9.
18. Fain O, Braun T, Stirnemann J, Fenaux P. Systemic and autoimmune manifestations in myelodysplastic syndromes. Rev Med Interne 2011;32:552-9.
19. Giannouli S, Tzoanopoulos D, Ritis K, Kartalis G, Moutsopoulos HM, Voulgarelis M. Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann Rheum Dis 2004;63:578-82.
20. Kiladjian JJ, Visentin G, Viey E, Chevret S, Eclache V, Stirnemann J, Bourhis JH, Chouaib S, Fenaux P, Caignard A. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes. Haematologica 2008;93:381-9.
21. Ma L, Ceuppens J, Kasran A, Delforge M, Boogaerts M, Vandenberghe P. Immature and mature monocyte-derived dendritic cells in myelodysplastic syndromes of subtypes refractory anemia or refractory anemia with ringed sideroblasts display an altered cytokine profile. Leuk Res 2007;31:1373-82.